I own em both, but I am really amazed at the discrepancy in market caps for both companys. SGEN at 5 billion, INCY at 8 billion... Sgen in a downtrend, INCY hitting new highs on a daily basis. Anyone here want to comment on these 2 emerging biotechs????
1) Look at SGEN's enormous short position; then look at INCY's.
2) Myelofibrosis has a higher incidence than the CD30+ lymphomas, and Adcetris is currently approved for only a fraction of the number of incident cases.